Search for other papers by Yi Chen in
Google Scholar
PubMed
Search for other papers by Wen Zhang in
Google Scholar
PubMed
Search for other papers by Chi Chen in
Google Scholar
PubMed
Search for other papers by Yuying Wang in
Google Scholar
PubMed
Search for other papers by Ningjian Wang in
Google Scholar
PubMed
Search for other papers by Yingli Lu in
Google Scholar
PubMed
Objective
We aimed to evaluate whether thyroid hormones, autoimmune and thyroid homeostasis status were related to bone turnover in type 2 diabetes.
Methods
The data were obtained from a cross-sectional study, the METAL study. In this study, 4209 participants (2059 men and 2150 postmenopausal women) with type 2 diabetes were enrolled. Thyroid function, thyroid antibodies and three bone turnover markers (BTMs), including a large N-mid fragment of osteocalcin (N-MID osteocalcin), β-C-terminal cross-linked telopeptides of type I collagen (β-CTX) and procollagen type I N-terminal propeptide (P1NP), were measured. Thyroid homeostasis parameters, including the sum activity of step-up deiodinases (SPINA-GD), thyroid secretory capacity (SPINA-GT), Jostel’s TSH index (TSHI) and the thyrotroph thyroid hormone resistance index (TTSI), were calculated. The associations of thyroid parameters with BTMs were analyzed using linear regression.
Results
Free and total triiodothyronine were positively associated with N-MID osteocalcin and P1NP in both sexes and positively associated with β-CTX in postmenopausal women. Thyroid-stimulating hormone was negatively associated with β-CTX in postmenopausal women, and free thyroxine was negatively associated with N-MID osteocalcin and P1NP in men. SPINA-GD was positively associated with N-MID osteocalcin and P1NP in both sexes. There was a positive relationship of SPINA-GT with β-CTX, a negative relationship of TTSI with β-CTX, and a negative relationship of TSHI with β-CTX and P1NP in postmenopausal women.
Conclusions
Among men and postmenopausal women with type 2 diabetes, significant associations were observed between N-MID osteocalcin, β-CTX and P1NP with thyroid function and thyroid homeostasis. Further prospective studies are warranted to understand the causal relationship and underlying mechanism.
Comprehensive Heart Failure Center, University & University Hospital Würzburg, Würzburg, Germany
Search for other papers by Ann-Cathrin Koschker in
Google Scholar
PubMed
Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Bodo Warrings in
Google Scholar
PubMed
Division of Cardiology, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Caroline Morbach in
Google Scholar
PubMed
Search for other papers by Florian Seyfried in
Google Scholar
PubMed
Search for other papers by Nicole Rickert in
Google Scholar
PubMed
Search for other papers by Pius Jung in
Google Scholar
PubMed
Search for other papers by Andreas Geier in
Google Scholar
PubMed
Search for other papers by Ulrich Dischinger in
Google Scholar
PubMed
Search for other papers by Maike Krauthausen in
Google Scholar
PubMed
Search for other papers by Martin J Herrmann in
Google Scholar
PubMed
Department of General, Visceral, Transplant, Vascular, and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Christine Stier in
Google Scholar
PubMed
Division of Cardiology, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Stefan Frantz in
Google Scholar
PubMed
Search for other papers by Uwe Malzahn in
Google Scholar
PubMed
Division of Cardiology, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany
Search for other papers by Stefan Störk in
Google Scholar
PubMed
Comprehensive Heart Failure Center, University & University Hospital Würzburg, Würzburg, Germany
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Search for other papers by the WAS Study Group in
Google Scholar
PubMed
Obesity is a rapidly emerging health problem and an established risk factor for cardiovascular diseases. Bariatric surgery profoundly reduces body weight and mitigates sequelae of obesity. The open, randomized controlled Würzburg Adipositas Studie (WAS) trial compares the effects of Roux-en-Y gastric bypass (RYGB) vs psychotherapy-supported lifestyle modification in morbidly obese patients. The co-primary endpoint addresses 1-year changes in cardiovascular function (peak VO2 during cardiopulmonary exercise testing) and the quality of life (QoL) (Short-Form-36 physical functioning scale). Prior to randomization, all included patients underwent a multimodal anti-obesity treatment for 6–12 months. Thereafter, the patients were randomized and followed through month 12 to collect the primary endpoints. Afterwards, patients in the lifestyle group could opt for surgery, and final visit was scheduled for all patients 24 months after randomization. Sample size calculation suggested to enroll 90 patients in order to arrive at minimally 22 patients per group evaluable for the primary endpoint. Secondary objectives were to quantify changes in body weight, left ventricular hypertrophy, systolic and diastolic function (by echocardiography and cardiac MRI), functional brain MRI, psychometric scales, and endothelial and metabolic function. WAS enrolled 93 patients (72 women, median age 38 years, BMI 47.5 kg/m2) exhibiting a relevantly compromised exercise capacity (median peakVO2 18.3 mL/min/kg) and the QoL (median physical functioning scale 50). WAS is the first randomized controlled trial focusing on the effects of RYGB on cardiovascular function beyond hypertension. In addition, it will provide a wealth of high-quality data on the cerebral, psychiatric, hepatic, and metabolic function in obese patients after RYGB.
Search for other papers by Michelle J Galvan in
Google Scholar
PubMed
Search for other papers by Michael J Sanchez in
Google Scholar
PubMed
Australian Institute for Musculoskeletal Science (AIMSS), Victoria University, Melbourne, Victoria, Australia
Search for other papers by Andrew J McAinch in
Google Scholar
PubMed
Search for other papers by Jeffrey D Covington in
Google Scholar
PubMed
Search for other papers by Jason B Boyle in
Google Scholar
PubMed
Search for other papers by Sudip Bajpeyi in
Google Scholar
PubMed
Introduction/purpose
Most US adults (54%) do not meet the minimum exercise recommendations by the American College of Sports Medicine. Neuromuscular electrical stimulation (NMES) is a novel alternate strategy to induce muscle contraction. However, the effectiveness of NMES to improve insulin sensitivity and energy expenditure is unclear. The purpose of this study was to investigate the effects of 4 weeks of NMES on glucose tolerance in a sedentary overweight or obese population.
Methods
Participants (n = 10; age: 36.8 ± 3.8 years; BMI = 32 ± 1.3 kg/m2) were randomized into either control or NMES group. All participants received bilateral quadriceps stimulation (12 sessions; 30 min/session; three times/week at 50 Hz and 300 µs pulse width) altering pulse amplitude to either provide low-intensity sensory level (control; tingling sensation) or at high-intensity neuromuscular level (NMES; maximum tolerable levels with visible muscle contraction). Glucose tolerance was assessed by a 3-h oral glucose tolerance test (OGTT), and substrate utilization was measured by indirect calorimetry and body composition via dual X-ray absorptiometry at baseline and after 4 weeks of NMES intervention.
Results
Control and NMES groups had comparable fasting blood glucose, glucose tolerance, substrate utilization, and muscle mass at baseline. Four weeks of NMES resulted in a significant improvement in glucose tolerance measured by OGTT, whereas no change was observed in the control group. There was no change in substrate utilization and muscle mass in both control and NMES groups.
Conclusion
NMES is a novel and effective strategy to improve glucose tolerance in an at-risk overweight or obese sedentary population.
Search for other papers by Chengnan Guo in
Google Scholar
PubMed
Search for other papers by Yixi Xu in
Google Scholar
PubMed
Search for other papers by Yange Ma in
Google Scholar
PubMed
Search for other papers by Xin Xu in
Google Scholar
PubMed
Search for other papers by Fang Peng in
Google Scholar
PubMed
Search for other papers by Hui-hui Li in
Google Scholar
PubMed
Search for other papers by Dongzhen Jin in
Google Scholar
PubMed
Search for other papers by Shu-zhen Zhao in
Google Scholar
PubMed
Search for other papers by Zhezheng Xia in
Google Scholar
PubMed
Search for other papers by Mengyuan Lai in
Google Scholar
PubMed
Search for other papers by Mingzhu Che in
Google Scholar
PubMed
Search for other papers by Ruogu Huang in
Google Scholar
PubMed
Search for other papers by Yanan Wang in
Google Scholar
PubMed
Search for other papers by Depeng Jiang in
Google Scholar
PubMed
Search for other papers by Chao Zheng in
Google Scholar
PubMed
Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China
National Clinical Research Center for Ocular Diseases, Wenzhou, Zhejiang, China
Search for other papers by Guangyun Mao in
Google Scholar
PubMed
Although previous studies demonstrate that trehalose can help maintain glucose homeostasis in healthy humans, its role and joint effect with glutamate on diabetic retinopathy (DR) remain unclear. We aimed to comprehensively quantify the associations of trehalose and glutamate with DR. This study included 69 pairs of DR and matched type 2 diabetic (T2D) patients. Serum trehalose and glutamate were determined via ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry system. Covariates were collected by a standardized questionnaire, clinical examinations and laboratory assessments. Individual and joint association of trehalose and glutamate with DR were quantified by multiple conditional logistic regression models. The adjusted odds of DR averagely decreased by 86% (odds ratio (OR): 0.14; 95% CI: 0.06, 0.33) with per interquartile range increase of trehalose. Comparing with the lowest quartile, adjusted OR (95% CI) were 0.20 (0.05, 0.83), 0.14 (0.03, 0.63) and 0.01 (<0.01, 0.05) for participants in the second, third and fourth quartiles of trehalose, respectively. In addition, as compared to their counterparts, T2D patients with lower trehalose (<median) and higher glutamate (≥median) had the highest odds of DR (OR: 36.81; 95% CI: 6.75, 200.61). An apparent super-multiplicative effect of trehalose and glutamate on DR was observed, whereas relative excess risk due to interaction was not significant. The study suggests that trehalose is beneficial to inhibit the occurrence of DR and synergistically decreases the risk of DR with reduced glutamate. Our findings also provide new insights into the mechanisms of DR and further longitudinal studies are required to confirm these findings.
Search for other papers by Xue-Lian Zhang in
Google Scholar
PubMed
Search for other papers by Xinyi Zhao in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Yong Wu in
Google Scholar
PubMed
Search for other papers by Wen-qing Huang in
Google Scholar
PubMed
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong, China
Search for other papers by Jun-jiang Chen in
Google Scholar
PubMed
Search for other papers by Peijie Hu in
Google Scholar
PubMed
Search for other papers by Wei Liu in
Google Scholar
PubMed
Search for other papers by Yi-Wen Chen in
Google Scholar
PubMed
Search for other papers by Jin Hao in
Google Scholar
PubMed
Search for other papers by Rong-Rong Xie in
Google Scholar
PubMed
Search for other papers by Hsiao Chang Chan in
Google Scholar
PubMed
Search for other papers by Ye Chun Ruan in
Google Scholar
PubMed
Search for other papers by Hui Chen in
Google Scholar
PubMed
Search for other papers by Jinghui Guo in
Google Scholar
PubMed
Objective
The beneficial effect of angiotensin(1–7) (Ang(1–7)), via the activation of its receptor, MAS-1, has been noted in diabetes treatment; however, how Ang(1–7) or MAS-1 affects insulin secretion remains elusive and whether the endogenous level of Ang(1–7) or MAS-1 is altered in diabetic individuals remains unexplored. We recently identified an important role of cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated Cl− channel, in the regulation of insulin secretion. Here, we tested the possible involvement of CFTR in mediating Ang(1–7)’s effect on insulin secretion and measured the level of Ang(1–7), MAS-1 as well as CFTR in the blood of individuals with or without type 2 diabetes.
Methods
Ang(1–7)/MAS-1/CFTR pathway was determined by specific inhibitors, gene manipulation, Western blotting as well as insulin ELISA in a pancreatic β-cell line, RINm5F. Human blood samples were collected from 333 individuals with (n = 197) and without (n = 136) type 2 diabetes. Ang(1–7), MAS-1 and CFTR levels in the human blood were determined by ELISA.
Results
In RINm5F cells, Ang(1–7) induced intracellular cAMP increase, cAMP-response element binding protein (CREB) activation, enhanced CFTR expression and potentiated glucose-stimulated insulin secretion, which were abolished by a selective CFTR inhibitor, RNAi-knockdown of CFTR, or inhibition of MAS-1. In human subjects, the blood levels of MAS-1 and CFTR, but not Ang(1–7), were significantly higher in individuals with type 2 diabetes as compared to those in non-diabetic healthy subjects. In addition, blood levels of MAS-1 and CFTR were in significant positive correlation in type-2 diabetic but not non-diabetic subjects.
Conclusion
These results suggested that MAS-1 and CFTR as key players in mediating Ang(1–7)-promoted insulin secretion in pancreatic β-cells; MAS-1 and CFTR are positively correlated and both upregulated in type 2 diabetes.
Search for other papers by Yanmei Lou in
Google Scholar
PubMed
Search for other papers by Yanyan Zhang in
Google Scholar
PubMed
Search for other papers by Ping Zhao in
Google Scholar
PubMed
Search for other papers by Pei Qin in
Google Scholar
PubMed
Search for other papers by Changyi Wang in
Google Scholar
PubMed
Search for other papers by Jianping Ma in
Google Scholar
PubMed
Search for other papers by Xiaolin Peng in
Google Scholar
PubMed
Search for other papers by Hongen Chen in
Google Scholar
PubMed
Search for other papers by Dan Zhao in
Google Scholar
PubMed
Search for other papers by Shan Xu in
Google Scholar
PubMed
Search for other papers by Li Wang in
Google Scholar
PubMed
Search for other papers by Ming Zhang in
Google Scholar
PubMed
Search for other papers by Dongsheng Hu in
Google Scholar
PubMed
Search for other papers by Fulan Hu in
Google Scholar
PubMed
We aimed to assess the association between fasting plasma glucose (FPG) change trajectory and incident hypertension among Chinese population. This cohort study included 11,791 adults aged 18–80 years without hypertension at first entry and who completed at least four follow-ups between 2009 and 2016. Logistic regression was used to estimate odds ratios (ORs) and 95% CIs for the association between FPG change trajectory and probability of hypertension. During a median follow-up of 5.10 years (total person–years 61,887.76), hypertension developed in 2177 participants. After adjusting for baseline potential confounders, the probability of hypertension increased with the increasing FPG change trajectory (adjusted OR (aOR) 1.22, 95% CI 1.07–1.40), bell-shape trajectory (aOR 1.15, 95% CI 1.02–1.30) and other-shape trajectory (aOR 1.13, 95% CI 1.02–1.25) which showed a higher variability of FPG compared to the decreasing group. In addition, the increasing FPG change trajectory was associated with a higher probability of hypertension compared with the decreasing group regardless of age and BMI but was only significant in males and in those with normal FPG at baseline. Our study indicates that the increasing FPG change trajectory determines the highest risk of hypertension, demonstrating the importance of maintaining low and stable levels of FPG, especially in males and in those with normal FPG.
Search for other papers by Wenjun Long in
Google Scholar
PubMed
Search for other papers by Tuo Zhou in
Google Scholar
PubMed
Search for other papers by Xiuping Xuan in
Google Scholar
PubMed
Search for other papers by Qiuli Cao in
Google Scholar
PubMed
Search for other papers by Zuojie Luo in
Google Scholar
PubMed
Search for other papers by Yingfen Qin in
Google Scholar
PubMed
Search for other papers by Qin Ning in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Xuemei Xie in
Google Scholar
PubMed
Intrauterine growth restriction combined with postnatal accelerated growth (CG-IUGR) could lead to long-term detrimental metabolic outcomes characterized by insulin resistance. As an indispensable co-receptor of Wnt signaling, LRP6 plays a critical role in the susceptibility of metabolic disorders. However, whether LRP6 is involved in the metabolic programing is still unknown. We hypothesized that CG-IUGR programed impaired insulin sensitivity through the impaired LRP6-mediated Wnt signaling in skeletal muscle. A CG-IUGR rat model was employed. The transcriptional and translational alterations of the components of the Wnt and the insulin signaling in the skeletal muscle of the male CG-IUGR rats were determined. The role of LRP6 on the insulin signaling was evaluated by shRNA knockdown or Wnt3a stimulation of LRP6. Compared with controls, the male CG-IUGR rats showed an insulin-resistant phenotype, with impaired insulin signaling and decreased expression of LRP6/β-catenin in skeletal muscle. LRP6 knockdown led to reduced expression of the IR-β/IRS-1 in C2C12 cell line, while Wnt3a-mediated LRP6 expression increased the expression of IRS-1 and IGF-1R but not IR-β in the primary muscle cells of male CG-IUGR rats. The impaired LRP6/β-catenin/IGF-1R/IRS-1 signaling is probably one of the critical mechanisms underlying the programed impaired insulin sensitivity in male CG-IUGR.
